AR084001A1 - Monobactamas y su uso en el tratamiento de infecciones bacterianas - Google Patents
Monobactamas y su uso en el tratamiento de infecciones bacterianasInfo
- Publication number
- AR084001A1 AR084001A1 ARP110104404A ARP110104404A AR084001A1 AR 084001 A1 AR084001 A1 AR 084001A1 AR P110104404 A ARP110104404 A AR P110104404A AR P110104404 A ARP110104404 A AR P110104404A AR 084001 A1 AR084001 A1 AR 084001A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- bacterial infections
- phenylalkyl
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de monobactama y su uso para tratar infecciones bacterianas.Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que cada uno de R1 y R2 es independientemente hidrógeno, alquilo C1-6 o fenilalquilo C1-6 opcionalmente sustituido, en los que los restos fenilo y alquilo C1-6 del fenilalquilo C1-6 están opcionalmente sustituidos; o R1 y R2 juntos, con el átomo de carbono a que están unidos, forman un cicloalquilo C3-6 opcionalmente sustituido o un heterociclo de 4 - 6 miembros opcionalmente sustituido; E es C(H), C(F), C(Cl) o N; X es -O-C(=O)-, -NH-C(=O)-, -NH-SO2-, -NH-C(=N-CN)-, -NH-T- o triazol; L está ausente, -(CH2)p-, -(CH2)p-NH-(CH2)q-, (CH2)p-O-(CH2)q-, -(CH2)p-C(=O)-NH-(CH2)q-, -(CH2)p-NH-C(=O)-(CH2)q-, -CH(CH3)-NH-C(=O)-(CH2)q-, -(CH2)p-NH-C(=O)-NH-(CH2)q-, -CH(CH3)-NH-C(=O)-NH-(CH2)q-, -(CH2)p-T-SO2-NH-(CH2)q-, -(CH2)p-T-(CH2)q, -(CH2)p-T-C(=O)-NH-(CH2)q-, -(CH2)p-T-(CH2)q-NH-C(=O)-, -NH-(CH2)p-T-, -O-(CH2)p-T-, -(CH2)p-Y-C(=O)-(CH2)q- o -(CH2)p-Y-(CH2)q-; T es un fenilo opcionalmente sustituido o un heteroarilo de 5 ó 6 miembros opcionalmente sustituido; Y es un heterociclo de 4 - 6 miembros opcionalmente sustituido; cada uno de p y q es independientemente 0, 1, 2 ó 3; A es un resto seleccionado del grupo de formulas (2); y R3 es hidrógeno, alquilo C1-3 o OH; con la condición de que la fórmula (1) no incluya ácido 2-(((1-(2-aminotiazol-4-il)-2-(((2S,3R)-2-((3-((1,5-dihidroxi-4-oxo-1,4-dihidropiridin-2-il)metil)ureido)metil)-4-oxo-1-sulfoazetidin-3-il)amino)-2-oxoetilideno)amino)oxi)-2-metilpropanoico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41757510P | 2010-11-29 | 2010-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084001A1 true AR084001A1 (es) | 2013-04-17 |
Family
ID=45315854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104404A AR084001A1 (es) | 2010-11-29 | 2011-11-25 | Monobactamas y su uso en el tratamiento de infecciones bacterianas |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20120302542A1 (es) |
| EP (1) | EP2646436B1 (es) |
| JP (1) | JP5777725B2 (es) |
| KR (1) | KR101514587B1 (es) |
| CN (1) | CN103228652B (es) |
| AR (1) | AR084001A1 (es) |
| AU (1) | AU2011336209B2 (es) |
| CA (1) | CA2815821C (es) |
| DK (1) | DK2646436T3 (es) |
| ES (1) | ES2542431T3 (es) |
| IL (1) | IL226052A0 (es) |
| MX (1) | MX2013005994A (es) |
| SG (1) | SG190007A1 (es) |
| TW (1) | TW201247661A (es) |
| UY (1) | UY33754A (es) |
| WO (1) | WO2012073138A1 (es) |
| ZA (1) | ZA201304479B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015099107A1 (ja) | 2013-12-26 | 2015-07-02 | 塩野義製薬株式会社 | 含窒素６員環誘導体およびそれらを含有する医薬組成物 |
| TWI714525B (zh) | 2014-03-24 | 2021-01-01 | 瑞士商諾華公司 | 用於治療細菌感染之單內醯胺（ｍｏｎｏｂａｃｔａｍ）有機化合物 |
| CN108137573B (zh) | 2015-09-23 | 2021-06-11 | 诺华股份有限公司 | 单环内酰胺抗生素的盐和固体形式 |
| CN105481812B (zh) * | 2015-11-30 | 2020-04-21 | 重庆天奕恒化科技有限公司 | 一种5-苄氧基-4-氧代-4h-吡喃-2-羧酸的制备方法 |
| EP3390357B1 (en) | 2015-12-15 | 2021-11-10 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds for the treatment of bacterial infections |
| US10407421B2 (en) | 2016-03-07 | 2019-09-10 | Merck Sharp & Dohme Corp | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
| CN107641119B (zh) | 2016-07-21 | 2019-11-08 | 中国科学院上海药物研究所 | 单环β-内酰胺-铁载体轭合物及其制备方法和用途 |
| EP3661933B1 (en) | 2017-08-02 | 2022-03-23 | Novartis AG | Process for preparing 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid |
| WO2019070492A1 (en) | 2017-10-02 | 2019-04-11 | Merck Sharp & Dohme Corp. | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| KR102786898B1 (ko) * | 2019-11-22 | 2025-03-25 | 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 | 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제 |
| AU2020397059A1 (en) | 2019-12-06 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| CN111303144B (zh) * | 2019-12-13 | 2020-11-27 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
| US12528804B2 (en) | 2021-03-31 | 2026-01-20 | Fedora Pharmaceuticals Inc. | Lactivicin compounds, their preparation and use as antibacterial agents |
| KR20230163532A (ko) | 2021-03-31 | 2023-11-30 | 페도라 파마슈티칼스 인코포레이티드 | 락티비신 화합물, 이의 제조 및 항균제로서의 용도 |
| WO2022235077A1 (ko) * | 2021-05-07 | 2022-11-10 | 한국생명공학연구원 | 신규 사이드로포어 화합물 및 이를 이용한 금속 나노입자 복합체 |
| CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
| GEAP202416514A (en) | 2021-11-18 | 2024-08-26 | Merck Sharp & Dohme Llc | Chromane amidine monobactam antibiotics |
| JP7671398B2 (ja) * | 2021-11-18 | 2025-05-01 | メルク・シャープ・アンド・ドーム・エルエルシー | クロマンアミジンモノバクタム抗生物質 |
| EP4511116A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN115304594B (zh) * | 2022-10-12 | 2023-02-14 | 苏州二叶制药有限公司 | 磺酰脲环取代的化合物的盐型及其晶型 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7541487A (en) * | 1986-05-23 | 1987-12-22 | Upjohn Company, The | N-1 substituted sulfonylaminocarbonyl, c-4 substituted monobactams |
| EP2308874B1 (en) | 2005-12-07 | 2013-01-23 | Basilea Pharmaceutica AG | Bridged monobactams useful as beta-lactamase inhibitors |
| CN102964296B (zh) | 2007-03-28 | 2015-03-25 | 阿普泰克斯科技公司 | 去铁酮的氟化衍生物 |
| JP2012512863A (ja) | 2008-12-19 | 2012-06-07 | ファイザー・インク | モノカルバム |
-
2011
- 2011-11-15 DK DK11794237.5T patent/DK2646436T3/en active
- 2011-11-15 JP JP2013541445A patent/JP5777725B2/ja not_active Expired - Fee Related
- 2011-11-15 KR KR1020137016718A patent/KR101514587B1/ko not_active Expired - Fee Related
- 2011-11-15 ES ES11794237.5T patent/ES2542431T3/es active Active
- 2011-11-15 MX MX2013005994A patent/MX2013005994A/es active IP Right Grant
- 2011-11-15 EP EP11794237.5A patent/EP2646436B1/en not_active Not-in-force
- 2011-11-15 CN CN201180057264.5A patent/CN103228652B/zh not_active Expired - Fee Related
- 2011-11-15 WO PCT/IB2011/055104 patent/WO2012073138A1/en not_active Ceased
- 2011-11-15 AU AU2011336209A patent/AU2011336209B2/en not_active Ceased
- 2011-11-15 SG SG2013031752A patent/SG190007A1/en unknown
- 2011-11-15 CA CA2815821A patent/CA2815821C/en not_active Expired - Fee Related
- 2011-11-24 TW TW100143172A patent/TW201247661A/zh unknown
- 2011-11-25 AR ARP110104404A patent/AR084001A1/es not_active Application Discontinuation
- 2011-11-28 UY UY0001033754A patent/UY33754A/es not_active Application Discontinuation
- 2011-11-29 US US13/306,581 patent/US20120302542A1/en not_active Abandoned
-
2013
- 2013-02-27 US US13/778,670 patent/US20130252935A1/en not_active Abandoned
- 2013-04-29 IL IL226052A patent/IL226052A0/en unknown
- 2013-06-18 ZA ZA2013/04479A patent/ZA201304479B/en unknown
-
2015
- 2015-01-29 US US14/608,826 patent/US20150148326A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012073138A1 (en) | 2012-06-07 |
| JP5777725B2 (ja) | 2015-09-09 |
| CN103228652A (zh) | 2013-07-31 |
| AU2011336209B2 (en) | 2015-03-19 |
| JP2013544276A (ja) | 2013-12-12 |
| DK2646436T3 (en) | 2015-06-29 |
| MX2013005994A (es) | 2013-07-15 |
| KR101514587B1 (ko) | 2015-04-22 |
| TW201247661A (en) | 2012-12-01 |
| AU2011336209A1 (en) | 2013-05-30 |
| HK1184462A1 (en) | 2014-01-24 |
| ES2542431T3 (es) | 2015-08-05 |
| IL226052A0 (en) | 2013-06-27 |
| EP2646436B1 (en) | 2015-05-27 |
| US20150148326A1 (en) | 2015-05-28 |
| ZA201304479B (en) | 2014-03-26 |
| CN103228652B (zh) | 2015-02-18 |
| SG190007A1 (en) | 2013-06-28 |
| CA2815821A1 (en) | 2012-06-07 |
| US20120302542A1 (en) | 2012-11-29 |
| UY33754A (es) | 2012-06-29 |
| KR20130112054A (ko) | 2013-10-11 |
| US20130252935A1 (en) | 2013-09-26 |
| EP2646436A1 (en) | 2013-10-09 |
| CA2815821C (en) | 2015-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084001A1 (es) | Monobactamas y su uso en el tratamiento de infecciones bacterianas | |
| AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| ES2490266T3 (es) | Derivados azacíclicos como inhibidores de HSL | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR083026A1 (es) | Derivados de ciclohexenona y composiciones para el tratamiento del cancer de pulmon | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| JP2013544276A5 (es) | ||
| CY1118879T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| JP2013507434A5 (es) | ||
| ECSP088479A (es) | Derivados de oxadiazol | |
| EA201400232A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-циклилэтил}-1н-[1,2,4]триазольные соединения | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR083017A1 (es) | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol | |
| AR051326A1 (es) | Pirazolobenzodiazepinas disustituidas | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| EA201400234A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4(4-галогенфенокси)фенил]-2-алкинилоксиэтил}-1н-[1,2,4]триазолные соединения | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
| AR087148A1 (es) | Imidazopiridazinas | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
| AR079448A1 (es) | Inhibidores de la esfingosina quinasa | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |